Organon & Co. (NYSE:OGN) Receives $18.00 Consensus PT from Brokerages

Organon & Co. (NYSE:OGN - Get Free Report) has been given a consensus rating of "Hold" by the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $18.00.

OGN has been the topic of a number of recent research reports. Morgan Stanley lowered their target price on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Piper Sandler cut their price target on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a report on Thursday, May 15th. Evercore ISI lowered Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. Finally, Barclays cut their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th.

Insider Transactions at Organon & Co.

In related news, CFO Matthew M. Walsh purchased 11,400 shares of the firm's stock in a transaction on Monday, May 5th. The stock was purchased at an average cost of $8.82 per share, with a total value of $100,548.00. Following the completion of the purchase, the chief financial officer now owns 144,484 shares in the company, valued at approximately $1,274,348.88. This trade represents a 8.57% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kirke Weaver acquired 8,045 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were bought at an average price of $9.21 per share, for a total transaction of $74,094.45. Following the acquisition, the insider now directly owns 52,489 shares of the company's stock, valued at approximately $483,423.69. This trade represents a 18.10% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 102,345 shares of company stock worth $902,430. Company insiders own 1.96% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millstone Evans Group LLC bought a new stake in shares of Organon & Co. during the fourth quarter valued at approximately $29,000. Ransom Advisory Ltd acquired a new stake in Organon & Co. in the 1st quarter valued at $32,000. Larson Financial Group LLC increased its stake in Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock valued at $33,000 after purchasing an additional 1,734 shares in the last quarter. Riverview Trust Co raised its holdings in Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after buying an additional 1,292 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after buying an additional 672 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Organon & Co. Trading Up 4.9%

Organon & Co. stock traded up $0.43 during trading hours on Friday, reaching $9.12. 6,116,678 shares of the company's stock traded hands, compared to its average volume of 3,256,912. The firm's 50 day moving average is $11.40 and its 200-day moving average is $13.97. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $23.10. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of 2.74, a PEG ratio of 0.90 and a beta of 0.75. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.89 by $0.13. The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.53 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm's revenue was down 6.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.22 EPS. On average, analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Monday, May 12th will be paid a $0.02 dividend. The ex-dividend date of this dividend is Monday, May 12th. This represents a $0.08 annualized dividend and a dividend yield of 0.88%. Organon & Co.'s payout ratio is 2.78%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.